Additional immunosuppressive factors within the TME, including indoleamine 2,3-dioxygenase (IDO) and interleukin-6 (IL-6), recruit myeloid cells and promote lymphocyte differentiation into regulatory T cells (Tregs), leading to dampened anti-tumor T-cell responses [21]. The gene discussed is IL6; the disease is neoplasm.